New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2013
12:30 EDTPRGOPerrigo announces launch of betamethasone valerate foam 0.12%
Perrigo announced that it has begun commercial shipments of betamethasone valerate foam 0.12%, the generic equivalent of Luxiq Foam, consistent with the date certain launch settlement previously announced. Cobrek Pharmaceuticals, , which was recently acquired by Perrigo, was first to file, making the product eligible for 180 days of marketing exclusivity. Perrigo is entitled to receive 100% of the profits from net sales of the product due to the Cobrek acquisition. Betamethasone valerate foam 0.12% is indicated for the relief of corticosteroid-responsive skin conditions of the scalp (scalp psoriasis). Brand annual sales were approximately $40M as measured by Symphony Health.
News For PRGO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2015
11:50 EDTPRGOPerrigo releases full statement of Abbott CEO regarding Mylan stake
Subscribe for More Information
07:53 EDTPRGOMylan to hold a conference call for Perrigo shareholders
Subscribe for More Information
October 8, 2015
09:32 EDTPRGOPerrigo, Hain Celestial, Hutchison China begins to sell infant formula in China
Subscribe for More Information
October 7, 2015
09:35 EDTPRGOMylan potential acquisition of Perrigo looks questionable says Bernstein
Subscribe for More Information
October 5, 2015
10:52 EDTPRGOFlamel confirms exclusive licensing agreement with Perrigo
Subscribe for More Information
09:56 EDTPRGOPerrigo and Flamel enter into exclusive licensing agreement for LiquiTime
Perrigo (PRGO) and Flamel (FLML) announced that they have entered into an exclusive licensing agreement for LiquiTime(R) extended release suspension. The technology will be utilized in the development of a portfolio of extended release suspension products intended for the U.S. OTC marketplace.
September 29, 2015
12:35 EDTPRGOPerrigo shareholders pressure company to explore sale, Reuters says
Certain Perrigo (PRGO) shareholders have requested that company explore a sale, hoping for an alternative to Mylan's (MYL) approximately $25B hostile bid, Reuters reports, citing people familiar with the matter. The pressure represents a challenge to Perrigo's defense strategy, the report says. Some of the company's shareholders view Novartis (NVS), Sanofi (SNY), Procter & Gamble (PG), and Colgate-Palmolive (CL) as potential suitors, the report says. Reference Link
12:23 EDTPRGOPerrigo shareholders pressure company to explore sale, Reuters says
Subscribe for More Information
September 28, 2015
07:46 EDTPRGOUBS to hold a field trip
Subscribe for More Information
September 25, 2015
13:51 EDTPRGOBMO's pharma predictions for rest of year include take on Mylan, Perrigo
BMO Capital analyst David Maris rolled out his rest of year predictions for the Specialty Pharmaceuticals space. Among them is his belief that Mylan (MYL) will be unsuccessful in acquiring Perrigo (PRGO). Perrigo will either be acquired by another company or make an acquisition itself, Maris tells investors in a research note. His other predictions include Jazz Pharmaceuticals (JAZZ) proving to be a good buying opportunity amidst the current negative sentiment and ZS Pharma (ZSPH) offering upside following the recent pullback given the potential for a near-term buyout and prospects for its "best in class drug for hyperkalemia" winning approval in 2016.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use